Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation



      Patients with atrial fibrillation often have cardiovascular risk factors or known comorbid disease, yet the use of evidence-based primary and secondary prevention cardiac therapy among atrial fibrillation outpatients is unknown.


      Using baseline data collected between June 2010 and August 2011 from 174 sites participating in ORBIT-AF, a US national registry of patients with atrial fibrillation coordinated from Durham, NC, we examined professional guideline-recommended evidence-based therapy use for cardiovascular comorbid conditions and risk factors. Multivariable logistic regression was used to identify factors associated with receipt of all indicated evidence-based therapy.


      Among 10,096 enrolled patients, 93.5% were eligible for one or more evidence-based therapies. Among those eligible, 46.6% received all indicated therapies: 62.3% received an antiplatelet agent, 72.3% received a beta-blocker, 59.5% received an angiotensin-converting enzyme or angiotensin receptor blocker, 15.3% received an aldosterone antagonist, 65.7% received a statin, and 58.8% received an implantable cardioverter-defibrillator. A minority of patients with coronary artery disease, diabetes mellitus, heart failure, and peripheral vascular disease received all indicated therapies (25.1%, 43.2%, 42.5%, and 43.4%, respectively). A total of 52.4% of patients had controlled hypertension and 74.6% of patients with hyperlipidemia received a statin. Factors associated with nonreceipt of all indicated therapies included frailty, comorbid illness, geographic region, and antiarrhythmic drug therapy.


      The majority of eligible atrial fibrillation outpatients did not receive all guideline-recommended therapies for cardiovascular comorbid conditions and risk factors. This represents a potential opportunity to improve atrial fibrillation patients' quality of care and outcomes.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Braunwald E.
        Shattuck lecture—cardiovascular medicine at the turn of the millenium: Triumphs, concerns, and opportunities.
        N Engl J Med. 1997; 337: 1360-1369
        • Lloyd-Jones D.M.
        • Wang T.J.
        • Leip E.P.
        • et al.
        Lifetime risk for development of atrial fibrillation: the Framingham Heart Study.
        Circulation. 2004; 110: 1042-1046
        • Roger V.L.
        • Go A.S.
        • Lloyd-Jones D.M.
        • et al.
        Heart disease and stroke statistics—2012 update: a report from the American Heart Association.
        Circulation. 2012; 125: e2-e220
        • Roger V.L.
        • Go A.S.
        • Lloyd-Jones D.M.
        • et al.
        Heart disease and stroke statistics—2011 update: a report from the American Heart Association.
        Circulation. 2011; 123: e18-e209
        • Go A.S.
        • Hylek E.M.
        • Phillips K.A.
        • et al.
        Prevalence of diagnosed atrial fibrillation in adults; national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study.
        JAMA. 2001; 285: 2370-2375
        • Wolf P.A.
        • Dawber T.R.
        • Thomas E.
        • Kannel W.B.
        Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Heart Study.
        Neurology. 1978; 28: 973-977
        • Benjamin E.J.
        • Wolf P.A.
        • D'Agostino R.B.
        • Silbershatz H.
        • Kannel W.B.
        • Levy D.
        Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.
        Circulation. 1998; 98: 946-952
        • Wang T.J.
        • Massaro J.M.
        • Levy D.
        • et al.
        A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study.
        JAMA. 2003; 290: 1049-1056
        • Lip G.Y.
        • Nieuwlaat R.
        • Pisters R.
        • Lane D.A.
        • Crijns H.J.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.
        Chest. 2010; 137: 263-272
        • Conen D.
        • Chae C.U.
        • Glynn R.J.
        • et al.
        Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation.
        JAMA. 2011; 305: 2080-2087
        • Jahangir A.
        • Lee V.
        • Friedman P.A.
        • et al.
        Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study.
        Circulation. 2007; 115: 3050-3056
        • Piccini J.P.
        • Fraulo E.S.
        • Ansell J.E.
        • et al.
        Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF.
        Am Heart J. 2011; 162 (606.e1–612.e1)
        • Smith Jr., S.C.
        • Benjamin E.J.
        • Bonow R.O.
        • et al.
        AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.
        Circulation. 2011; 124: 2458-2473
        • Jessup M.
        • Abraham W.T.
        • Casey D.E.
        • et al.
        2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.
        Circulation. 2009; 119: 1977-2016
        • Rooke T.W.
        • Hirsch A.T.
        • Misra S.
        • et al.
        2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines.
        Circulation. 2011; 124: 2020-2045
      1. American Diabetes Association. Standards of medical care in diabetes—2011.
        Diabetes Care. 2011; 34: S11-S61
        • Grundy S.M.
        • Cleeman J.I.
        • Merz C.N.
        • et al.
        Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines.
        Circulation. 2004; 110: 227-239
        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • et al.
        The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report.
        JAMA. 2003; 289: 2560-2572
        • Hess P.L.
        • Greiner M.A.
        • Fonarow G.C.
        • et al.
        Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to medicare claims.
        Clin Cardiol. 2012; 35: 649-657
        • Nasr I.A.
        • Bouzamondo A.
        • Hulot J.S.
        • Dubourg O.
        • Le Heuzey J.Y.
        • Lechat P.
        Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: A meta-analysis.
        Eur Heart J. 2007; 28: 457-462
        • Liu T.
        • Li L.
        • Korantzopoulos P.
        • Liu E.
        • Li G.
        Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies.
        Int J Cardiol. 2008; 126: 160-170
        • Schneider M.P.
        • Hua T.A.
        • Bohm M.
        • Wachtell K.
        • Kjeldsen S.E.
        • Schmieder R.E.
        Prevention of atrial fibrillation by renin-angiotensin system inhibition: A meta-analysis.
        J Am Coll Cardiol. 2010; 55: 2299-2307
        • Ueng K.C.
        • Tsai T.P.
        • Yu W.C.
        • et al.
        Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation.
        Eur Heart J. 2003; 24: 2090-2098
        • Madrid A.H.
        Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.
        Circulation. 2002; 106: 331-336
        • Williams R.S.
        • deLemos J.A.
        • Dimas V.
        • Reisch J.
        • Hill J.A.
        • Naseem R.H.
        Effect of spironolactone on patients with atrial fibrillation and structural heart disease.
        Clin Cardiol. 2011; 34: 415-419
        • Fauchier L.
        • Pierre B.
        • de Labriolle A.
        • Grimard C.
        • Zannad N.
        • Babuty D.
        Antiarrhythmic effect of statin therapy and atrial fibrillation: a meta-analysis of randomized controlled trials.
        J Am Coll Cardiol. 2008; 51: 828-835
        • Fuster V.
        • Ryden L.E.
        • Cannom D.S.
        • et al.
        2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines.
        Circulation. 2011; 123: e269-e367
        • Fonarow G.C.
        • Albert N.M.
        • Curtis A.B.
        • et al.
        Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).
        Circulation. 2010; 122: 585-596
        • Gaede P.
        • Lund-Anderson H.
        • Parving H.H.
        • Pedersen O.
        Effect of a multifactorial intervention on mortality in type 2 diabetes.
        N Engl J Med. 2008; 358: 580-591
        • Newby L.K.
        • LaPointe N.M.
        • Chen A.Y.
        • et al.
        Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease.
        Circulation. 2006; 113: 203-212
        • Saydah S.H.
        • Fradkin J.
        • Cowie C.C.
        Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.
        JAMA. 2004; 291: 335-342
        • Fonarow G.C.
        • Yancy C.W.
        • Albert N.M.
        • et al.
        Heart failure care in the outpatient cardiology practice setting: Findings from IMPROVE HF.
        Circ Heart Fail. 2008; 1: 98-106
        • Jackevicius C.A.
        • Mamdani M.
        • Tu J.V.
        Adherence with statin therapy in elderly patients with and without acute coronary syndromes.
        JAMA. 2002; 288: 462-467
        • Egan B.M.
        • Zhao Y.
        • Axon R.N.
        US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008.
        JAMA. 2010; 303: 2043-2050
        • Hirsch A.T.
        • Criqui M.H.
        • Treat-Jacobson D.
        • et al.
        Peripheral arterial disease detection, awareness, and treatment in primary care.
        JAMA. 2001; 286: 1317-1324
        • Afilalo J.
        • Karunananthan S.
        • Eisenberg M.J.
        • Alexander K.P.
        • Bergman H.
        Role of frailty in patients with cardiovascular disease.
        Am J Cardiol. 2009; 103: 1616-1621
        • Flint K.M.
        • Matlock D.D.
        • Lindenfeld J.
        • Allen L.A.
        Frailty and the selection of patients for destination therapy left ventricular assist device.
        Circ Heart Fail. 2012; 5: 286-293
        • Alexander K.P.
        • Newby L.K.
        • Cannon C.P.
        • et al.
        Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
        Circulation. 2007; 115: 2549-2569
        • Alexander K.P.
        • Newby L.K.
        • Armstrong P.W.
        • et al.
        Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
        Circulation. 2007; 115: 2570-2589
        • Boutitie F.
        • Boissel J.P.
        • Connolly S.J.
        • et al.
        Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT investigators.
        Circulation. 1999; 99: 2268-2275
        • Thomas K.L.
        • Al-Khatib S.M.
        • Lokhnygina Y.
        • et al.
        Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
        Am Heart J. 2008; 155: 87-93
        • Go A.S.
        • Hylek E.M.
        • Borowsky L.H.
        • Phillips K.A.
        • Selby J.V.
        • Singer D.E.
        Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study.
        Ann Intern Med. 1999; 131: 927-934
        • Kowey P.R.
        • Reiffel J.A.
        • Myerburg R.
        • et al.
        Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS registry).
        Am J Cardiol. 2010; 105: 1130-1134